Where science meets patients: Sanford Children’s Research Center hosts inaugural symposium
The event celebrated 16 years of progress at the Center and connected scientists with the people most impacted by their work.
The Sanford Children’s Health Research Center at Sanford Burnham Prebys recently hosted its first-ever Children’s Health Research Symposium, which brought scientists and families together to learn about the latest research tackling childhood diseases.
“We’re all here because we want to improve the health of children,” said President and CEO David A. Brenner, M.D., during his opening comments. “But this event also shows the amazing amount of collaboration and collegiality across San Diego, because we have all types of people together from different backgrounds who want to develop therapies and cures for children affected by disease.”
The Sanford Children’s Health Research Center was established in 2008 with the help of a generous gift from Institute namesake T. Denny Sanford. Since then, the Center has been a world leader in children’s health research.
“T. Denny Sanford made an investment in children’s health 15 years ago, and I think that investment has paid off pretty well so far,” said Center director Hudson Freeze, Ph.D., in his introduction to the first scientific session. Freeze is among the world’s leading experts on congenital disorders of glycosylation (CDG), a rare group of genetic disorders that can cause serious, sometimes fatal, malfunctions of different organs and systems in the body.
“We've published over 600 scientific papers, and about half of those are translational studies, which means they’re helping turn scientific discoveries into real treatments for patients,” adds Freeze.
The day included presentations from researchers at Sanford Burnham Prebys, as well as from other research organizations studying childhood diseases. However, the highlight of the event was the afternoon reception, in which scientists had the opportunity to mingle and share a meal with families affected by rare childhood diseases.
Each researcher briefly introduced the family affected by the illness the scientist studies. This list included many longtime friends of the Institute, such as Damian Omler, who lives with a rare form of CDG; and Morgan Fischer, who was born with soft bone disease. Today, thanks to the help of a drug developed based on the research of Institute professor José Luis Millán, Ph.D., Morgan is a thriving teenager. This drug is also helping other children living with soft bone disease, including 10-year-old Aubrey Britt, who was in attendance with her family as well.
“Something so important that we keep as a tradition for scientific events at our Institute is to involve families that have been touched by the work of our faculty,” said Freeze. “They’re why we’re all here.”
The full list of talks included:
Sanford Children’s Health Research Center
- José Luis Millán, Ph.D. “Developing therapeutics for soft bones and ectopic calcification disorders”
- Duc Dong, Ph.D. “From hope for few to drug for many—why rare is precious”
- Evan Snyder, M.D. Ph.D. “A clinical trial using human neural stem cells for neuroprotection in perinatal asphyxia, a major cause of cerebral palsy in kids”
- Anne Bang, Ph.D. “Drug screens of human-induced pluripotent stem cell (hiPSC) derived neuronal networks on multi-electrode arrays”
- Pamela Itkin-Ansari, Ph.D. “Proinsulin misfolding in diabetes”
- Yu Yamaguchi, M.D. Ph.D. “Multiple hereditary exostoses—from genetics to potential drug targets"
- Hudson Freeze, Ph.D. “Fucose therapy: Revising bedrock biochemistry"
- David Pearce, Ph.D. “From rare diseases to type-1 diabetes: Research that impacts children at Sanford Health”
Frontiers in Congenital Disorders of Glycosylation Consortium
- Eva Morava, M.D., Ph.D. “Clinical trials in Glyco-land”
- Ethan Perlstein, Ph.D. “Precision drug repurposing: Patient avatar to pioneer study to Phase 3 trial”
UC San Diego
- Lars Bode, Ph.D. “Human milk-based therapeutics and diagnostics to protect preterm babies from necrotizing enterocolitis”
- Stephanie Cherqui, Ph.D. “Hematopoietic stem cell gene therapy for cystinosis: Mechanism of action and clinical trial update”